NO800473L - Intrauterin anordning. - Google Patents
Intrauterin anordning.Info
- Publication number
- NO800473L NO800473L NO800473A NO800473A NO800473L NO 800473 L NO800473 L NO 800473L NO 800473 A NO800473 A NO 800473A NO 800473 A NO800473 A NO 800473A NO 800473 L NO800473 L NO 800473L
- Authority
- NO
- Norway
- Prior art keywords
- drug
- aromatic
- group
- guanidine
- elements
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims description 107
- 229940079593 drug Drugs 0.000 claims description 101
- 125000003118 aryl group Chemical group 0.000 claims description 95
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 48
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 37
- 239000011248 coating agent Substances 0.000 claims description 30
- 238000000576 coating method Methods 0.000 claims description 30
- 229920000642 polymer Polymers 0.000 claims description 30
- 239000011159 matrix material Substances 0.000 claims description 29
- 210000004291 uterus Anatomy 0.000 claims description 28
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 22
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 16
- 150000001409 amidines Chemical class 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000003509 anti-fertility effect Effects 0.000 claims description 10
- 230000001567 anti-fibrinolytic effect Effects 0.000 claims description 9
- 229920006037 cross link polymer Polymers 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 230000000636 anti-proteolytic effect Effects 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- 229920002988 biodegradable polymer Polymers 0.000 claims description 6
- 239000004621 biodegradable polymer Substances 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- PKSBDZOBYIKNGY-UHFFFAOYSA-N (4-nitrophenyl) 4-(diaminomethylideneamino)benzoate;hydrochloride Chemical compound Cl.C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 PKSBDZOBYIKNGY-UHFFFAOYSA-N 0.000 claims description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 125000000320 amidine group Chemical group 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 7
- 230000000996 additive effect Effects 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- DNOSZYUZVCJLMM-UHFFFAOYSA-N carbamimidoylazanium;benzoate Chemical compound NC(N)=[NH2+].[O-]C(=O)C1=CC=CC=C1 DNOSZYUZVCJLMM-UHFFFAOYSA-N 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- CKROEWVDNACFEK-UHFFFAOYSA-N 3-[4-(3-amino-3-iminoprop-1-enyl)cyclohexyl]prop-2-enimidamide Chemical compound NC(=N)C=CC1CCC(C=CC(N)=N)CC1 CKROEWVDNACFEK-UHFFFAOYSA-N 0.000 claims 1
- UWMJUUOFQFMZEU-UHFFFAOYSA-N 4-[4-(4-carbamimidoylphenoxy)cyclohexyl]oxybenzenecarboximidamide Chemical compound C1=CC(C(=N)N)=CC=C1OC1CCC(OC=2C=CC(=CC=2)C(N)=N)CC1 UWMJUUOFQFMZEU-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- JKXCZYCVHPKTPK-UHFFFAOYSA-N hydrate;trihydrochloride Chemical compound O.Cl.Cl.Cl JKXCZYCVHPKTPK-UHFFFAOYSA-N 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 description 11
- 150000002357 guanidines Chemical class 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 206010027514 Metrorrhagia Diseases 0.000 description 8
- 208000007106 menorrhagia Diseases 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- -1 aromatic amidines Chemical class 0.000 description 6
- GMJFVGRUYJHMCO-UHFFFAOYSA-N dibrompropamidine Chemical compound BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br GMJFVGRUYJHMCO-UHFFFAOYSA-N 0.000 description 6
- 229960000493 dibrompropamidine Drugs 0.000 description 6
- 230000002357 endometrial effect Effects 0.000 description 6
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 5
- 230000004720 fertilization Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003433 contraceptive agent Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 4
- 229960000401 tranexamic acid Drugs 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000002254 contraceptive effect Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- 108090000113 Plasma Kallikrein Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 201000003511 ectopic pregnancy Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- PTAWCSGASQQSSW-UHFFFAOYSA-N 2-[2-[4-[2-(diaminomethylideneamino)ethenyl]cyclohexyl]ethenyl]guanidine Chemical compound NC(N)=NC=CC1CCC(C=CN=C(N)N)CC1 PTAWCSGASQQSSW-UHFFFAOYSA-N 0.000 description 1
- WXSXSTKKTSSTJW-UHFFFAOYSA-N 2-[3-bromo-4-[3-[2-bromo-4-(diaminomethylideneamino)phenoxy]propoxy]phenyl]guanidine Chemical compound BrC1=CC(N=C(N)N)=CC=C1OCCCOC1=CC=C(N=C(N)N)C=C1Br WXSXSTKKTSSTJW-UHFFFAOYSA-N 0.000 description 1
- AJGAPBXTFUSKNJ-UHFFFAOYSA-N 2-cyclohexylguanidine Chemical compound NC(=N)NC1CCCCC1 AJGAPBXTFUSKNJ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- WCBGYTIRMLODMA-UHFFFAOYSA-N ethyl 4-(diaminomethylideneamino)benzoate Chemical compound CCOC(=O)C1=CC=C(N=C(N)N)C=C1 WCBGYTIRMLODMA-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
Landscapes
- Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/055,900 US4495934A (en) | 1978-07-25 | 1979-07-09 | IUD Arrangement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO800473L true NO800473L (no) | 1981-01-12 |
Family
ID=22000897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO800473A NO800473L (no) | 1979-07-09 | 1980-02-21 | Intrauterin anordning. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4495934A (de) |
| EP (1) | EP0024781B1 (de) |
| JP (1) | JPS5611056A (de) |
| AU (1) | AU538984B2 (de) |
| CH (1) | CH646862A5 (de) |
| DE (1) | DE3068836D1 (de) |
| NO (1) | NO800473L (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ200564A (en) * | 1982-05-10 | 1987-03-06 | Ahi Operations Ltd | Device for slowly releasing chemicals into body cavities of animals |
| US4568338A (en) * | 1983-09-22 | 1986-02-04 | C. R. Bard, Inc. | Preformed catheter |
| GB8805286D0 (en) * | 1988-03-05 | 1988-04-07 | Schering Agrochemicals Ltd | Trypanocides |
| MX16687A (es) * | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
| DE59108548D1 (de) * | 1990-08-10 | 1997-03-27 | Pacesetter Ab | Implantierbare Geräte und Materialien |
| EP0495749A1 (de) * | 1991-01-14 | 1992-07-22 | Ciba-Geigy Ag | Bipyridyle |
| FR2690616B1 (fr) * | 1992-04-30 | 1999-12-10 | Michel Mida | Nouveau dispositif intra-uterin a usage contraceptif. |
| FI93922C (fi) * | 1993-06-17 | 1995-06-26 | Leiras Oy | Vaikuttavaa ainetta luovuttava laite |
| JPH10279499A (ja) * | 1997-04-04 | 1998-10-20 | Takeda Chem Ind Ltd | 子宮粘膜適用製剤 |
| FR2811218B1 (fr) | 2000-07-05 | 2003-02-28 | Patrice Suslian | Dispositif implantable destine a corriger l'incontinence urinaire |
| US20060205995A1 (en) | 2000-10-12 | 2006-09-14 | Gyne Ideas Limited | Apparatus and method for treating female urinary incontinence |
| US8167785B2 (en) | 2000-10-12 | 2012-05-01 | Coloplast A/S | Urethral support system |
| GB0025068D0 (en) | 2000-10-12 | 2000-11-29 | Browning Healthcare Ltd | Apparatus and method for treating female urinary incontinence |
| GB0108088D0 (en) | 2001-03-30 | 2001-05-23 | Browning Healthcare Ltd | Surgical implant |
| AU2003269934A1 (en) | 2002-08-02 | 2004-02-23 | C.R. Bard, Inc. | Self anchoring sling and introducer system |
| GB0307082D0 (en) | 2003-03-27 | 2003-04-30 | Gyne Ideas Ltd | Drug delivery device and method |
| JP2007521237A (ja) * | 2003-09-05 | 2007-08-02 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 微生物感染症処置用の新規アミジン化合物 |
| GB0411360D0 (en) | 2004-05-21 | 2004-06-23 | Mpathy Medical Devices Ltd | Implant |
| US7862552B2 (en) * | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| WO2008121750A2 (en) * | 2007-03-28 | 2008-10-09 | Vance Products Incorporated D/B/A | Medical device for delivering a bioactive and method of use thereof |
| US8282612B1 (en) | 2008-03-07 | 2012-10-09 | Denise H. Miller | Methods and devices for intrauterine absorption |
| EP2140860A1 (de) | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | Verbessertes Verhütungsverfahren |
| US10028858B2 (en) | 2011-07-11 | 2018-07-24 | Medicines360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
| USD718435S1 (en) | 2012-05-30 | 2014-11-25 | Medicines360 | Intrauterine insertion device |
| US9078786B1 (en) | 2012-10-19 | 2015-07-14 | Denise H. Miller | Methods and devices for collecting body fluids |
| US20150320766A1 (en) * | 2012-12-14 | 2015-11-12 | Laboratoire Hra-Pharma | Copper intrauterine device |
| US11571328B2 (en) | 2018-04-09 | 2023-02-07 | Medicines360 | IUD insertion devices |
| US20200261258A1 (en) | 2019-02-19 | 2020-08-20 | Medicines360 | Devices, systems, methods and kits for insertion and removal of iuds |
| US12544256B2 (en) | 2022-09-16 | 2026-02-10 | Medicines360 | IUD removal devices, and related methods and kits |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB376806A (en) * | 1931-04-07 | 1932-07-07 | William Hogan Lewers | Improvements in polymethylenediguanidine compounds and their process of manufacture |
| GB516289A (en) * | 1938-06-24 | 1939-12-29 | May & Baker Ltd | New therapeutically valuable diguanidine compounds |
| GB938042A (en) * | 1961-03-30 | 1963-09-25 | Wellcome Found | Phenoxyalkanes |
| BE789524A (fr) * | 1971-09-30 | 1973-01-15 | Alza Corp | Dispositif de liberation de medicaments |
| US3895103A (en) * | 1971-11-22 | 1975-07-15 | Alza Corp | Intrauterine contraceptive device containing certain pharmaceutically acceptable steroids |
| US3817248A (en) * | 1972-11-06 | 1974-06-18 | Alza Corp | Self powered device for delivering beneficial agent |
| US4178361A (en) * | 1973-09-10 | 1979-12-11 | Union Corporation | Sustained release pharmaceutical composition |
| FR2250520B1 (de) * | 1973-11-09 | 1977-04-15 | Cournut Rene | |
| GB1503499A (en) * | 1974-08-23 | 1978-03-08 | Fisons Ltd | Antiprotozoal method and composition |
| US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4215200A (en) * | 1978-10-02 | 1980-07-29 | Cornell Research Foundation, Inc. | Chemically and enzymatically modified collagen hemostatic agent |
-
1979
- 1979-07-09 US US06/055,900 patent/US4495934A/en not_active Expired - Lifetime
- 1979-11-21 AU AU53073/79A patent/AU538984B2/en not_active Ceased
- 1979-11-28 JP JP15412979A patent/JPS5611056A/ja active Pending
-
1980
- 1980-01-17 CH CH37880A patent/CH646862A5/de not_active IP Right Cessation
- 1980-01-29 EP EP80300259A patent/EP0024781B1/de not_active Expired
- 1980-01-29 DE DE8080300259T patent/DE3068836D1/de not_active Expired
- 1980-02-21 NO NO800473A patent/NO800473L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU5307379A (en) | 1981-01-15 |
| AU538984B2 (en) | 1984-09-06 |
| EP0024781A1 (de) | 1981-03-11 |
| DE3068836D1 (en) | 1984-09-13 |
| JPS5611056A (en) | 1981-02-04 |
| US4495934A (en) | 1985-01-29 |
| CH646862A5 (de) | 1984-12-28 |
| EP0024781B1 (de) | 1984-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO800473L (no) | Intrauterin anordning. | |
| NO800474L (no) | Intrauterin anordning. | |
| US4359046A (en) | IUD Arrangement | |
| Choe et al. | Hysteroscopic treatment of septate uterus with neodymium-YAG laser | |
| NO800475L (no) | Befruktningshindrende middel for bruk i forbindelse med en intrauterin anordning | |
| Gibbs et al. | Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms | |
| RU96102572A (ru) | Способ лечения преэклампсий и угрозы преждевременных родов композицией агента, способствующего сохранению беременности, и субстратом и/или донором синтазы окиси азота | |
| HUP0003784A2 (hu) | Fájdalmas menstruáció és koraszülés kezelésére alkalmas gyógyászati készítmény | |
| RU2329829C2 (ru) | Перекись в низкой концентрации для лечения или профилактики вагинальных инфекций | |
| US4381001A (en) | IUD Arrangement | |
| STEINLEITNER et al. | Pentoxifylline, a methylxanthine derivative, prevents postsurgical adhesion reformation in rabbits | |
| US4781926A (en) | Transdermal therapeutic composition | |
| Levy et al. | Selective blockade of the vasodepressor response to prostaglandin F2α in the anaesthetized rabbit | |
| KR100738724B1 (ko) | 자궁내막증 혹은 불임증의 치료, 혹은 임신력의 향상 | |
| JPH0794583B2 (ja) | 高含水高分子ゲル | |
| EA030035B1 (ru) | Применение s-этилизотиоурония диэтилфосфата для изготовления лекарственного средства для лечения нарушения матки | |
| Terzic et al. | Conservative management of massive hematoperitoneum caused by ovulation in a patient with severe form of von Willebrand disease--a case report | |
| Schwartz et al. | Formation, reduction, and treatment of adhesive disease | |
| Yeko et al. | A prospective series of unruptured ectopic pregnancies treated by tubal injection with hyperosmolar glucose | |
| US20240066106A1 (en) | Haemorrhage inhibiting compositions and methods involving the same | |
| SALZMANN et al. | Hepatic hemorrhage in pregnancy | |
| Feitsma et al. | Misoprostol in the management of postpartum haemorrhage | |
| Albert et al. | Nitrofurazone: vas irrigation as an adjunct in vasectomy | |
| Storment et al. | Tranexamic Acid (TA) | |
| Chowdhary et al. | Prevention of early recurrence of aneurysmal subarchnoid haemorrhage by tranexamic acid: a controlled clinical trial |